Advertisement

Topics

Astellas starts dosing gilteritinib patients in Phase III trial to treat AML

19:00 EDT 22 Aug 2017 | Net Resources International

Astellas Pharma has started dosing patients with gilteritinib in a Phase III MORPHO clinical trial for the treatment of acute myeloid leukaemia (AML).

Original Article: Astellas starts dosing gilteritinib patients in Phase III trial to treat AML

NEXT ARTICLE

More From BioPortfolio on "Astellas starts dosing gilteritinib patients in Phase III trial to treat AML"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...